Pharming Group NV 2023 AR2
The report highlights Pharming Group N.V.'s transformation into a multi-product, commercial rare disease biopharmaceutical company in 2023. Key achievements include a 10% growth in RUCONEST® revenues to US$227.1 million and the successful U.S. launch of Joenja® (leniolisib) for APDS, generating US$18.2 million in revenue. The company also advanced its pipeline with global regulatory filings for leniolisib and initiated pediatric clinical trials. Additionally, Pharming made significant progress on its ESG journey by conducting a double materiality assessment in accordance with the EU Corporate Sustainability Reporting Directive (CSRD) to prepare for mandatory reporting in 2025.
Company: Pharming Group NV
Sector: Health Care
Country: Netherlands
Year: 2023
Type: AR2
Pages: 201
Pharming Group NV
Annual Report
The report highlights Pharming Group N.V.'s transformation into a multi-product, commercial rare disease biopharmaceutical company in 2023. Key achievements include a 10% growth in RUCONEST® revenues to US$227.1 million and the successful U.S. launch of Joenja® (leniolisib) for APDS, generating US$18.2 million in revenue. The company also advanced its pipeline with global regulatory filings for leniolisib and initiated pediatric clinical trials. Additionally, Pharming made significant progress on its ESG journey by conducting a double materiality assessment in accordance with the EU Corporate Sustainability Reporting Directive (CSRD) to prepare for mandatory reporting in 2025.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Jan 1, 2023 - Dec 31, 2023
Fiscal Year
2023
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Employees